Background: Although high soy consumption may be associated with lower breast cancer risk in Asian populations, findings from epidemiological studies have been inconsistent. Objective: We investigated the effects of soy intake on breast cancer risk among Korean women according to their menopausal and hormone receptor status. Methods: We conducted a case-control study with 358 incident breast cancer patients and 360 age-matched controls with no history of malignant neoplasm. Dietary consumption of soy products was examined using a 103-item food frequency questionnaire. Results: The estimated mean intakes of total soy and isoflavones from this study population were 76.5 g per day and 15.0 mg per day, respectively. Using a multivariate logistic regression model, we found a significant inverse association between soy intake and breast cancer risk, with a dose-response relationship (odds ratios (OR) (95% confidence interval (CI)) for the highest vs the lowest intake quartile: 0.36 (0.20-0.64)). When the data were stratified by menopausal status, the protective effect was observed only among postmenopausal women (OR (95% CI) for the highest vs the lowest intake quartile: 0.08 (0.03-0.22)). The association between soy and breast cancer risk did not differ according to estrogen receptor (ER)/progesterone receptor (PR) status, but the estimated intake of soy isoflavones showed an inverse association only among postmenopausal women with ER þ /PR þ tumors. Conclusions: Our findings suggest that high consumption of soy might be related to lower risk of breast cancer and that the effect of soy intake could vary depending on several factors.
Introduction
Ecological and epidemiological studies have suggested that high soy consumption might explain the low incidence of breast cancer in Asian countries compared with Western countries (Pisani et al., 2002; Wu et al., 2008b) . Soybeans are the predominant source of isoflavones. Because of their structural similarity to 17b-estradiol, soy isoflavones may bind directly to the estrogen receptors (ERs) and modulate their functions (Messina and Wood, 2008) . Given the association between estrogen and breast cancer risk, it is biologically plausible that dietary soy intake may have an anticarcinogenic effect in the breast. Isoflavones are also known to act independent of the ERs through their antiproliferative, antiangiogenic, antioxidative and anti-inflammatory properties (Setchell et al., 2002) . In addition to isoflavones, soybeans also contain other bioactive components that may be associated with chemoprevention (for example, protease inhibitors, phenolic acids, lignans, phytosterols and saponins) (Allred et al., 2004) . Furthermore, several studies have reported possible synergistic effects of these components (Omoni and Aluko, 2005; Kim et al., 2008) . However, the association between soy consumption and breast cancer risk remains inconclusive in epidemiological studies (Trock et al., 2006; Wu et al., 2008b) . It has been suggested that the effect of soy consumption on breast cancer etiology may depend on several factors, including hormonal environment (Yamamoto et al., 2003; Hirose et al., 2005; Hwang et al., 2006) , receptor status (Linseisen et al., 2004; Suzuki et al., 2008; Zhang et al., 2009) , timing of soy exposure (Wu et al., 2002) , amount and profile of isoflavones in foods or supplements (Hsieh et al., 1998) , and individual metabolism and genetics (Setchell et al., 2002) .
The incidence of breast cancer in Korea is rapidly increasing with the westernization of lifestyle (for example, high-calorie and high-animal-fat diet, low parity and late first pregnancy) (Ahn, 2004) . However, Korean women still have a lower incidence of breast cancer than Western women, especially in older age groups (Ahn, 2004) . Given its high consumption of a wide variety of soy foods, the Korean population is appropriate for evaluating an association between soy consumption and breast cancer risk. Therefore, we aimed to examine the association of dietary intake of soy with breast cancer risk in a Korean population, also considering menopause and hormone receptor status. In addition, the association of estimated soy isoflavone intake and breast cancer risk was investigated.
Materials and methods

Study subjects
Eligible breast cancer cases were enrolled at the Center for Breast Cancer, National Cancer Center Hospital, Korea, between July 2007 and September 2008. Among 424 incident breast cancer patients aged 25-77 years admitted for surgery, 398 women agreed to participate in the study. After excluding patients with a previous history of cancer or the inability to cooperate in the interview, 383 patients were eligible for enrollment. The control group was recruited among visitors to a cancer screening program at the same hospital during the same time period. Among visitors to the cancer screening center, 723 women agreed to provide informed consent and submit a food frequency questionnaire (FFQ). After excluding women with a history of malignant neoplasms or other benign breast disease and those with missing information on dietary intake, 617 women were eligible for inclusion. Participants who reported an implausible daily energy intake (o600 or 43500 kcal) were excluded (four cases and two controls), and the controls were frequency matched to the cases using a 5-year age distribution. The final analysis included 358 cases and 360 controls. Study protocols and consent forms were approved by the institutional review board of the National Cancer Center Hospital (IRB protocol number NCCNCS 07-083).
Data collection
A trained dietitian conducted a face-to-face interview to collect information on demographics, lifestyle factors and diet using a structured questionnaire. Physical activity was measured using the short form of the International Physical Activity Questionnaire and summarized into metabolic equivalents of unit-minutes per week. A menstrual and reproductive history was also obtained, including age at menarche, menopausal status, age at menopause, postmenopausal hormone use and parity. Usual dietary intake was assessed with a validated FFQ with a list of 103 food items, 5 of which contain soy. The five soy foods included are legumes (black soybeans and green peas), tofu (soybean curd), soy milk, sprouts (mung bean sprouts and soybean sprouts) and fermented soy paste (soybean paste and fermented soybeans). All subjects were interviewed about their average frequencies of intake and portion sizes of specific foods during the previous year. Nine frequency categories (that is, never or rarely, once a month, two or three times a month, once or twice a week, three or four times a week, five or six times a week, once a day, twice a day and three times a day) and three portion sizes (that is, small, medium and large) were included in the FFQ. The average daily nutrient intake for each subject was measured by adding up the intake amount and the associated nutrient content per 100 g for each of the 103 foods. Total soy intake for each subject was estimated as the summation of the intakes of all soy foods tested. Total soy isoflavone intake was estimated from a Korean isoflavone database established by Park et al. (2007) . The validity of the FFQ used in this study has been tested using the 3-day dietary record as a gold standard in a total of 202 persons. The deattenuation correlation coefficient, percent agreement of the same plus adjacent quartile categories, percent exact agreement with the same quartile and percent gross misclassification for total isoflavone were 0.529, 72.4, 33.5 and 4.4%, respectively. ER and progesterone receptor (PR) status were analyzed by immunohistochemistry on tissue sections cut from formalinfixed, paraffin-embedded breast tumors (Ventana Medical Systems, Tucson, AZ, USA) (Nam et al., 2008) .
Statistical analyses w
2 -Tests and t-tests were used to compare the characteristics between cases and controls. Unconditional logistic regression models were used to examine the association between quartiles of soy foods or isoflavone intake and breast cancer risk, measured by odds ratios (ORs) and 95% confidence intervals (CIs). Intakes of soy foods and isoflavones were categorized on the basis of quartiles of the control distributions. The median intake of each quartile category of soy and isoflavone intake was used as a continuous variable to test for trends. We considered both age-adjusted and multivariate models. Multivariate models were adjusted for age, body mass index, family history of breast cancer, dietary supplement use, education level, occupation, smoking status, alcohol consumption, physical activity, age at menarche, parity and total energy intake. Additional adjustment for postmenopausal hormone use was implemented for the analysis of postmenopausal women. Energy adjustment for soy/isoflavone intake was done using the residual method described by Willett (1998) . We conducted subgroup analyses of soy intake and breast cancer risk by menopausal status and examined the potential effect modification. Statistical significance for the interaction was tested by using the likelihood ratio test comparing the model containing interaction with one containing only the main effects of two variables. We also investigated the effect of soy intake according to combined ER/PR status. SAS 9.1 software (SAS Institute Inc, Cary, NC, USA) was used to perform the calculations, and a two-sided P-value o0.05 was considered statistically significant.
Results
Compared with controls, cases had higher body mass indexes (P ¼ 0.003), were less likely to be dietary supplement users (P ¼ 0.001), had lower levels of education (Po0.001), were less likely to be in professional occupations (P ¼ 0.012), were older at menarche (Po0.001) and used less postmenopausal hormones (Po0.001) ( Table 1) . Data on selected dietary intake habits of the subjects are presented in Table 2 . The estimated mean intakes of soy and isoflavones in this study were 76.5 g per day and 15.0 mg per day, respectively. In general, the diets of the women in the case group involved significantly higher intakes of energy (P ¼ 0.032) and legumes (P ¼ 0.005), but lower intakes of total soy products (Po0.001), tofu (Po0.001), fermented soy paste (Po0.001), soy milk (P ¼ 0.008) and sprouts (Po0.001). Similar results were observed in pre-and postmenopausal women, but the associations were mostly stronger among postmenopausal women, except for legumes. Tofu and legumes were the major sources of isoflavones and provided 37.5 and 25.9% of total isoflavone intake, respectively. A significant difference between cases and controls in isoflavone intake was observed only in postmenopausal women. Table 3 presents adjusted ORs and 95% CIs of breast cancer risk for quartile levels of soy food and isoflavone intakes in pre-and postmenopausal women separately. In multivariate regression models, the protective effect of total soy intake was significant, with a dose-response relationship (OR (95% CI) for the highest vs the lowest intake quartile: 0.36 (0.20-0.64)). When we stratified the data by menopausal status, the significant inverse association was observed only among postmenopausal women (P-value for interaction ¼ 0.003). Five common soy foods consumed in Korea were also tested and showed slightly different results. Increased intake of tofu and fermented soy paste significantly reduced breast cancer risk among postmenopausal women. The intake of sprouts showed a significant protective effect in both pre-and postmenopausal women. The effect of isoflavones was observed only among postmenopausal women.
Of the 357 breast cancer cases tested for hormone receptor status, 215 (60.2%) were diagnosed with an ER þ /PR þ tumor; 32 (9.0%) had an ER þ /PRÀ tumor;11 (3.1%) had an ERÀ/PR þ tumor; and 99 (27.7%) had an ERÀ/PRÀ tumor. The OR estimates among ER þ /PRÀ tumors and ERÀ/PR þ tumors are not shown because they are based on small numbers and do not allow for meaningful interpretation. In multivariate logistic regression models, total soy intake showed a significant protective effect in a dose-response relationship among postmenopausal women regardless of hormone receptor status. However, the estimated isoflavone intake showed an inverse association in postmenopausal women with ER þ /PR þ tumors (OR (95% CI) for the highest vs the lowest intake quartile: 0.33 (0.12-0.89)), but not in postmenopausal women with ERÀ/PRÀ tumors (OR (95% CI) for the highest vs the lowest intake quartile: 0.59 (0.22-1.58)) ( Table 4 ).
Discussion
Our study found a statistically significant inverse association between soy food intake and the risk of breast cancer in postmenopausal women. Each soy food tested showed slightly different results. The effect of soy on breast cancer risk did not differ by ER/PR status, but the estimated isoflavone intake showed an inverse association with breast cancer risk only among postmenopausal women with ER þ /PR þ tumors. To date, the findings on the effect of soy on breast cancer risk in epidemiological studies have been inconclusive (Trock et al., 2006; Wu et al., 2008b) . Large differences in study results exist between the Asian and Western populations; Wu et al. (2008b) found a significant trend of decreasing risk with increasing soy consumption from a meta-analysis of the eight studies conducted in Asians, who are large consumers of soy. However, soy intake was unrelated to breast cancer risk in studies conducted in 11 Western populations with low soy consumption (Wu et al., 2008b) .
As endogenous estrogen has been recognized as a cause of breast cancer (Messina et al., 2006a) , the substantial decline of ovarian hormones after menopause might modify the effect of soy consumption in breast cancer etiology. The biological activity of isoflavones may differ by the hormonal milieu. Results from in vivo studies suggest that isoflavones have antiestrogenic effects in high-estrogen environments and estrogenic effects in low-estrogen environments (Messina et al., 2006a) . However, results of epidemiological studies are inconsistent; significant inverse associations have been found only in premenopausal women (Hirose et al., 1995) , only in postmenopausal women (Yamamoto et al., 2003; Wu et al., 2008a) or in both pre-and postmenopausal women (Wu et al., 1996) . Two meta-analyses have reported similar protective effects of soy on pre-and postmenopausal women (Trock et al., 2006; Wu et al., 2008b) . In our study, a significant association was found only among postmenopausal women. Some studies have suggested possible antiestrogenic effects (Duncan et al., 1999; Xu et al., 2000) and antiproliferative effects (Imhof and Molzer, 2008) of soy in postmenopausal women. In addition, the reported modified effects of hormone receptor status (Suzuki et al., 2008) , body mass index (Wu et al., 2008a) and equol status (Fuhrman et al., 2008) on soy-breast cancer associations in postmenopausal women also explain the inconsistent findings of previous studies. However, it is hard to explain the lack of such an inverse association among premenopausal Soy intake and breast cancer YA Cho et al women. One possible explanation is that the stronger protective effect of soy among postmenopausal women may be attributable to their lifestyle rather than to soy intake itself (Helferich et al., 2008) . Postmenopausal women may own more traditional lifestyle including a vegetablebased dietary pattern. Other dietary factors such as meat and alcohol consumption could also affect the association, but adjustment for these did not change our findings; thus, meat and alcohol consumption may not confound the association in this study. It is also possible that postmenopausal women have consumed a high amount of soy foods consistently during childhood or adolescence, the period at which soy consumption may have its greatest effect on breast cancer risk (Wu et al., 2002; Korde et al., 2009) . It has been suggested that the effect of soy on breast cancer etiology may differ according to several factors, including receptor status in breast cancer tissue and interindividual variability in metabolism and genetics. Subtypes of breast cancer may have different etiologies depending on ER/PR status (Li et al., 2003) . Several epidemiological studies have examined the effect of soy intake with stratification by receptor status but reported mixed findings. A case-control study in China found that a greater risk reduction was associated with ERÀ/PRÀ tumors than with ER þ /PR þ tumors (Zhang et al., 2009) . However, another case-control study in China found that the protective effect of soy protein intake on breast cancer risk was stronger with ER þ /PR þ receptor status than for other subtypes (Dai et al., 2001) . One case-control study in Japan observed a reduced risk only in patients with ER þ tumors (Suzuki et al., 2008) . We also found a possibly stronger protective effect of isoflavone intake on breast cancer risk among postmenopausal women with ER þ /PR þ tumors. Our findings may be plausible given that the anticarcinogenic effect of isoflavones comes from their antiestrogenic or estrogenic activity mediated by their affinity for ERs (Kuiper et al., 1998; Messina et al., 2006a) . However, isoflavones can exert hormonal and antiestrogenic effects in many ways without direct interaction with the ER (Kao et al., 1998; Makela et al., 1998) , and thus more studies are needed to elucidate the underlying mechanism. In addition, differences in intestinal bacterial metabolism can influence the absorption and metabolism of soy. Approximately 30% of the population is capable of producing equol, a metabolite of daidzein. As equol binds to ERs with greater efficacy than daidzein, the effects of soy intake on breast cancer risk are more pronounced among equol producers (Setchell et al., 2002; Fuhrman et al., 2008) . A gene-diet interaction may also affect the association (McCann et al., 2002) .
The effect of soybean-based foods on breast cancer risk may be affected by the foods' components and degree of processing. Most studies of the soy-breast cancer association have focused on the role of isoflavones. However, there is still no conclusive evidence to date showing whether the protective effects of soy are derived entirely from isoflavones, from soy protein itself, from other bioactive components or from a combination of these (Omoni and Aluko, 2005) . Total soy and isoflavone intakes in this study population were 76.5 ± 75.0 g per day and 15.0 ± 12.3 mg per day, respectively; isoflavone contents of each soy food are 3.9 ± 5.8 mg per day (25.9%) in legumes, 5.6 ± 5.2 mg per day (37.5%) in tofu, 2.4 ± 2.8 mg per day (16.2%) in fermented soy paste, 1.7 ± 5.5 mg per day (11.6%) in soy milk and 1.3 ± 1.8 mg per day (11.4%) in sprouts.
Soy intake and breast cancer YA Cho et al Table 3 ORs and 95% CIs of breast cancer risk in relation to intake of soybean products and isoflavones by menopausal status Test for trend calculated with the median intake for each category of soybean products or isoflavone intake as a continuous variable.
